Tag: ISHLT

MISSISSAUGA, Ontario – September 22, 2026 – Traferox Technologies, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the X°Port® Heart Preservation System, a device that enables static 10°C heart preservation during transport prior to transplantation “The FDA clearance of X°Port Heart marks an important milestone for Traferox and for the continued…

Last week, Traferox had the opportunity to welcome MP Fares Al Soud to our office in Mississauga. The visit covered a lot of ground. MP Al Soud toured the space and met the team behind Traferox’s world-class organ preservation and assessment systems: the engineers, scientists, and clinical specialists working to bring technology developed at Toronto…

MISSISSAUGA, Ontario — July 16, 2026 — Traferox Technologies, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the TorEx® Lung Perfusion System with TorEx Lung Perfusate (TLP), an ex vivo lung perfusion (EVLP) platform designed to enable functional assessment of donor lungs outside the body prior…

It was great to connect at ISHLT 2026 in Toronto. Whether you dropped by our booth or joined our symposium, it was a pleasure to interact with so many lung and heart transplant professionals from around the world. This year’s meeting highlighted the growing body of evidence for extended preservation and the real-world clinical impact…